Advert - Janssen-Cilag Ltd – Case AUTH/3436/12/20
Nurse led Stelara homecare service
-
Date posted21 April 2022
-
SanctionAdvertisement, Audit of company’s procedures, Public reprimand,
-
Case number/s
Janssen voluntarily admitted that it had failed to maintain oversight and high standards in relation to a nurse-led Stelara (ustekinumab) homecare service and was ruled in breach of the following clauses of the 2019 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 9.1 - Failing to maintain high standards
In addition, the Code of Practice Appeal Board required Janssen to be publicly reprimanded for its failure to have oversight or control of a patient-facing service for 28 months and for its delay in making its voluntary admission once the errors had come to the company’s attention; the company was also required to be audited and re-audited.